Boehringer Ingelheim, Tessellate Bio collaborate to develop precision treatments for hard-to-treat cancers Ruchika Sharma25 April 2025 12:30 PM ISTIngelheim: Boehringer Ingelheim and Tessellate Bio, a precision oncology company, have entered into a research collaboration and global license...
Boehringer Ingelheim appoints Shashank Deshpande as Chairman of Board of Managing Directors Ruchika Sharma18 April 2025 4:31 PM ISTIngelheim: Boehringer Ingelheim has announced that Shashank Deshpande, member of the Board of Managing Directors, has been appointed Chairman of the...
Boehringer Ingelheim, Cue Biopharma partner to develop next generation treatment for autoimmune, inflammatory diseases Ruchika Sharma16 April 2025 10:30 AM ISTBoston: Boehringer Ingelheim and Cue Biopharma, Inc. have announced a strategic research collaboration and license agreement to develop and...
Spesolimab Shows Promise for Generalized Pustular Psoriasis: Study Dr. Kamal Kant Kohli31 March 2025 9:15 PM ISTPost-hoc analyses of the EFFISAYIL 2 trial revealed improvements in Psoriasis Symptom Scale (PSS), Pain Visual Analog Scale (VAS), and Dermatology...
Submit More Data: CDSCO Panel tells Boehringer Ingelheim on Veterinary Drug Afoxolaner Dr. Divya Colin12 March 2025 6:30 PM ISTNew Delhi: In response to the proposal presented by Boehringer Ingelheim, the Subject Expert Committee (SEC) functional under the Central Drug...
Boehringer Ingelheim gets USFDA priority review for Zongertinib for HER2 (ERBB2)-mutant advanced non-small cell lung cancer treatment Ruchika Sharma20 Feb 2025 11:30 AM ISTIngelheim: Boehringer Ingelheim has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug...
Macleods Pharma Wins Legal Battle Over Linagliptin Patent Farhat Nasim21 Jan 2025 5:41 PM ISTNew Delhi: In a major setback to Boehringer Ingelheim, the Delhi High Court has upheld the maintainability of a revocation petition filed by...
Boehringer Ingelheim's Schizophrenia Drug iclepertin Fails Phase 3 Trial Dr. Kamal Kant Kohli19 Jan 2025 8:15 PM ISTBoehringer Ingelheim announced that its schizophrenia drug, iclepertin, did not achieve statistically significant improvements in cognition or...
Lupin buys 3 anti-diabetes trademarks from Boehringer Ingelheim Ruchika Sharma14 Dec 2024 11:30 AM ISTMumbai: Global pharma major Lupin Limited has announced the acquisition of anti-diabetes trademarks GIBTULIO, GIBTULIO MET and AJADUO from...
Boehringer Ingelheim launches EURICAN L4 vaccine for leptospirosis in dogs Ruchika Sharma1 Dec 2024 2:00 PM ISTIngelheim: Boehringer Ingelheim has begun its launch of EURICAN L4, delivering a new vaccine to protect dogs against the growing threat of...
Boehringer Ingelheim, Broad Institute of MIT and Harvard to develop treatments for people with mental health conditions Ruchika Sharma8 Nov 2024 9:00 AM ISTIngelheim: Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard have agreed...
GSK agrees to pay up to $2.2 bln to settle about 80000 Zantac lawsuits Ruchika Sharma10 Oct 2024 6:17 PM ISTNew York: Pharmaceutical giant GlaxoSmithKline (GSK) has agreed to pay up to $2.2 billion to settle most of lawsuits filed in U.S. state courts,...
